Clinical Trial Update: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation [Phase 3]

View source ↗

Summary

Phase 3 evaluation of the CoStar paclitaxel-eluting coronary stent catheter system has completed. The study focused on coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Conor Medsystems | Conditions: Coronary Disease | Phase 3 | Status: COMPLETED